Your shopping cart is currently empty

M8-B Hydrochloride is a selective transient receptor potential melastatin-8 (TRPM8) channel antagonist.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $30 | In Stock | In Stock | |
| 5 mg | $48 | In Stock | In Stock | |
| 10 mg | $68 | In Stock | In Stock | |
| 25 mg | $148 | In Stock | In Stock | |
| 50 mg | $238 | In Stock | In Stock | |
| 100 mg | $353 | In Stock | In Stock | |
| 200 mg | $493 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $58 | In Stock | In Stock |
| Description | M8-B Hydrochloride is a selective transient receptor potential melastatin-8 (TRPM8) channel antagonist. |
| In vivo | M8 B, a TRPM8 antagonist, can reduce body temperature.M8 B decreased the body temperature of rat pups and increased the latency to the first febrile seizure, implying a significant protective effect.?It also induced a significant anticonvulsant effect in PTZ but not electroshock induced convulsions.?M8 B showed anticonvulsant effects in both febrile and PTZ induced seizures.?M8 B had a hypothermic effect with significant protective effects on febrile and PTZ induced seizures. |
| Animal Research | Eight day old male Wistar rat pups were used for induction of febrile seizure.?M8 B and diazepam were injected intraperitoneally.?The rat pups were then transferred to a heated plexiglas chamber and the latency to the first febrile seizure was measured.?In addition, different groups of mice were pretreated with M8 B and received a convulsant dose of pentylenetetrazol (PTZ).?Latencies to stages 2 and 4 and duration of stage 5 seizure episodes were measured.The effect of M8 B on electroshock induced seizures was also investigated and hindlimb extension time was measured[1]. |
| Molecular Weight | 432.96 |
| Formula | C22H25ClN2O3S |
| Cas No. | 883976-12-3 |
| Smiles | Cl.COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 27.5 mg/mL (63.52 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.62 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.